Double maintains 1 strategies that include NUVL - Nuvalent, Inc.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FMTO | -16.81% | $37.82M | -99.94% | 0.00% |
LITB | -8.30% | $24.46M | -56.54% | 0.00% |
CME | -7.42% | $103.02B | +39.52% | 3.67% |
NEUE | -7.24% | $61.16M | +13.41% | 0.00% |
VSA | -7.07% | $6.89M | -41.29% | 0.00% |
KR | -6.83% | $44.58B | +28.80% | 1.91% |
CBOE | -6.49% | $23.79B | +30.06% | 1.07% |
ED | -6.30% | $37.25B | +11.82% | 3.26% |
K | -6.09% | $28.62B | +39.03% | 2.75% |
AGL | -5.76% | $923.11M | -64.26% | 0.00% |
VSTA | -5.62% | $326.42M | +15.63% | 0.00% |
MO | -5.50% | $100.19B | +30.90% | 6.79% |
LRN | -5.43% | $6.48B | +114.02% | 0.00% |
AWK | -4.69% | $27.60B | +12.08% | 2.21% |
STG | -4.31% | $27.62M | -29.46% | 0.00% |
ACI | -3.96% | $12.76B | +7.99% | 2.44% |
EXC | -2.58% | $44.12B | +18.98% | 3.56% |
GO | -2.11% | $1.35B | -35.94% | 0.00% |
CARV | -1.98% | $7.15M | -21.79% | 0.00% |
BTCT | -1.71% | $22.13M | +59.26% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 58.45% | $4.60B | 0.35% |
IBB | 54.28% | $5.23B | 0.45% |
GNOM | 51.52% | $41.00M | 0.5% |
PTH | 50.92% | $97.74M | 0.6% |
FBT | 50.30% | $1.03B | 0.56% |
ARKG | 50.18% | $927.51M | 0.75% |
PBE | 49.69% | $223.00M | 0.58% |
IWO | 48.01% | $11.24B | 0.24% |
XPH | 47.64% | $138.73M | 0.35% |
IWC | 47.18% | $784.70M | 0.6% |
BBH | 46.91% | $330.20M | 0.35% |
VTWO | 46.45% | $12.05B | 0.07% |
ISCG | 46.22% | $658.37M | 0.06% |
IWM | 46.18% | $63.57B | 0.19% |
SCHA | 45.57% | $16.81B | 0.04% |
KJAN | 45.54% | $300.25M | 0.79% |
VBK | 45.53% | $18.20B | 0.07% |
KJUL | 45.21% | $115.62M | 0.79% |
PINK | 45.01% | $130.02M | 0.5% |
SMMD | 44.81% | $1.41B | 0.15% |
Current Value
$73.981 Year Return
Current Value
$73.981 Year Return
Yahoo
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today outlined pipeline and business progress, reiterated key anticipated milestones, and reported first quarter 2025 financial results.
Finnhub
Nuvalent, Inc. reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported net loss was USD 84.58 million compared to USD 44.48 million a year...
Yahoo
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the publication of a manuscript in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research, which supports the rational molecular design of zidesamtinib, its novel and selective ROS1 inhibitor. Zidesamtinib is currently being evaluated in the ongoing ARROS-1 Phase 1/2 trial for p
Yahoo
We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at where Nuvalent, Inc. (NASDAQ:NUVL) stands against other takeover rumor stocks hedge funds are buying. Hedge funds tend to pile up on a stock that gains or is expected to gain positive […]
Yahoo
We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Nuvalent, Inc. (NASDAQ:NUVL) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic over President […]
Yahoo
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced two "Trial in Progress" poster presentations for its novel ALK-selective inhibitor, neladalkib, and novel HER2-selective inhibitor, NVL-330, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting from May 30 – June 5, 2025, in Chicago. Posters will be archived on the Nuvalent website at www.nuva
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
KYMR | 50.41% | $1.97B | -5.94% | 0.00% |
RVMD | 46.78% | $7.28B | +2.40% | 0.00% |
CRNX | 46.47% | $2.86B | -32.73% | 0.00% |
ROIV | 46.19% | $8.06B | +8.76% | 0.00% |
IDYA | 44.93% | $1.76B | -43.98% | 0.00% |
DNLI | 44.92% | $1.97B | -26.65% | 0.00% |
RARE | 44.84% | $3.31B | -9.37% | 0.00% |
COGT | 44.74% | $627.35M | -24.42% | 0.00% |
XNCR | 43.13% | $550.51M | -67.62% | 0.00% |
NRIX | 42.65% | $811.15M | -31.71% | 0.00% |
VERA | 42.38% | $1.27B | -46.06% | 0.00% |
ATXS | 42.32% | $279.35M | -45.06% | 0.00% |
XENE | 42.12% | $2.23B | -25.61% | 0.00% |
IMVT | 41.26% | $2.53B | -43.62% | 0.00% |
KRYS | 41.08% | $3.63B | -22.27% | 0.00% |
SYNA | 40.70% | $2.30B | -36.37% | 0.00% |
ASND | 40.65% | $9.88B | +19.00% | 0.00% |
DYN | 40.57% | $1.39B | -60.77% | 0.00% |
IMNM | 40.42% | $778.76M | -39.16% | 0.00% |
CLDX | 40.15% | $1.32B | -40.99% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -33.82% | $320.45M | 1.43% |
VIXY | -31.85% | $141.70M | 0.85% |
TAIL | -30.60% | $111.21M | 0.59% |
FTSD | -15.64% | $212.84M | 0.25% |
IVOL | -15.23% | $348.07M | 1.02% |
KCCA | -14.60% | $94.38M | 0.87% |
WEAT | -11.27% | $118.99M | 0.28% |
ULST | -11.11% | $660.43M | 0.2% |
TFLO | -10.91% | $7.03B | 0.15% |
TPMN | -9.87% | $30.91M | 0.65% |
CTA | -9.86% | $1.08B | 0.76% |
XHLF | -9.82% | $1.48B | 0.03% |
XONE | -8.22% | $616.52M | 0.03% |
USFR | -6.85% | $18.83B | 0.15% |
FXY | -5.43% | $858.65M | 0.4% |
UTWO | -5.35% | $380.80M | 0.15% |
AGZD | -5.35% | $106.82M | 0.23% |
BILS | -4.91% | $3.94B | 0.1356% |
SPTS | -4.88% | $5.74B | 0.03% |
SHYM | -4.49% | $323.12M | 0.35% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FTSM | -0.09% | $6.50B | 0.45% |
GBIL | 0.13% | $6.08B | 0.12% |
STPZ | 0.27% | $453.91M | 0.2% |
CLIP | 0.32% | $1.50B | 0.07% |
BUXX | 0.36% | $296.53M | 0.25% |
IBTH | -0.38% | $1.54B | 0.07% |
LDUR | 0.41% | $911.83M | 0.5% |
SMB | -0.51% | $269.90M | 0.07% |
BSCP | -0.67% | $3.41B | 0.1% |
UNG | -0.78% | $368.09M | 1.06% |
GSST | -0.87% | $884.31M | 0.16% |
IBTG | -0.90% | $1.91B | 0.07% |
BIL | -1.21% | $44.37B | 0.1356% |
XBIL | 1.25% | $779.01M | 0.15% |
IBMN | 1.30% | $449.34M | 0.18% |
JMST | 1.66% | $3.76B | 0.18% |
SHY | 1.81% | $24.24B | 0.15% |
IBTI | 1.82% | $1.02B | 0.07% |
IEI | 1.96% | $15.84B | 0.15% |
USDU | -2.04% | $169.24M | 0.5% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SO | 0.02% | $97.54B | +13.67% | 3.28% |
DG | -0.05% | $21.35B | -24.13% | 2.44% |
PLCE | -0.08% | $132.88M | -51.17% | 0.00% |
ALHC | -0.14% | $2.95B | +89.09% | 0.00% |
TPB | -0.21% | $1.30B | +123.98% | 0.39% |
CCEC | -0.25% | $1.02B | +3.91% | 2.65% |
CL | -0.27% | $74.80B | +1.51% | 2.18% |
PPC | 0.36% | $11.62B | +54.56% | 0.00% |
FUBO | -0.50% | $1.24B | +189.60% | 0.00% |
GNE | -0.53% | $558.38M | +37.93% | 1.45% |
ICL | -0.56% | $8.54B | +40.55% | 2.85% |
AEP | 0.58% | $54.77B | +16.30% | 3.58% |
BMRN | -0.82% | $11.23B | -21.39% | 0.00% |
LTM | -0.99% | $11.38B | -96.47% | 2.69% |
VZ | 1.06% | $182.69B | +7.44% | 6.22% |
VHC | -1.09% | $33.26M | +91.41% | 0.00% |
AIFU | -1.24% | $2.64B | -23.13% | 0.00% |
CCRN | 1.29% | $437.00M | -9.63% | 0.00% |
NOC | 1.29% | $69.00B | +7.36% | 1.29% |
HRTG | 1.30% | $735.16M | +178.73% | 0.00% |